{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:24:53Z","timestamp":1790727893742,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1053\/j.ajkd.2005.10.007","type":"journal-article","created":{"date-parts":[[2006,2,28]],"date-time":"2006-02-28T09:53:20Z","timestamp":1141120400000},"page":"263-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD"],"prefix":"10.1053","volume":"47","author":[{"given":"Daniel","family":"Coyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Batlle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rosansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fadem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2005.10.007_bib1","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1097\/01.ASN.0000034202.91413.EB","article-title":"The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease","volume":"13","author":"De Boer","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib2","first-page":"245","article-title":"Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure","volume":"49","author":"Panichi","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib3","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2005.10.007_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000081023","article-title":"Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study","volume":"24","author":"Gonzalez","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1681\/ASN.V104878","article-title":"Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism","volume":"10","author":"Felsenfeld","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.1995.201","article-title":"Bone disease in predialysis, hemodialysis, and CAPD patients","volume":"47","author":"Torres","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ki.1976.42","article-title":"Bone histology in incipient and advanced renal failure","volume":"9","author":"Malluche","year":"1976","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ki.1993.350","article-title":"Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease","volume":"44","author":"Hutchison","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/snep.2002.35965","article-title":"Renal osteodystrophy in chronic renal failure","volume":"22","author":"Ho","year":"2002","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca \u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000169030","article-title":"Hypocalcemia, morbidity, and mortality in end-stage renal disease","volume":"16","author":"Foley","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.10.007_bib14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib15","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"Lindberg","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.10.007_bib18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1681\/ASN.V11101857","article-title":"1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro","volume":"11","author":"Holliday","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.10.007_bib20","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.V11112088","article-title":"Calcemic activity of 19-nor-1,25(OH)(2)D(2) decreases with duration of treatment","volume":"11","author":"Brown","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"10.1053\/j.ajkd.2005.10.007_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/ajkd.2000.17667","article-title":"Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro","volume":"36","author":"Balint","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.10.007_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2005.10.007_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2005.10.007_bib25","first-page":"1595","article-title":"Calcitriol and calcium carbonate therapy in early chronic renal failure","volume":"9","author":"Bianchi","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2005.10.007_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2005.10.007_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","article-title":"Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure","volume":"56","author":"Rix","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/00365597809179725","article-title":"Degree and course of skeletal demineralization in patients with chronic renal insufficiency","volume":"12","author":"Madsen","year":"1978","journal-title":"Scand J Urol Nephrol"},{"key":"10.1053\/j.ajkd.2005.10.007_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2005.10.007_bib30","doi-asserted-by":"crossref","first-page":"16754","DOI":"10.1074\/jbc.M310271200","article-title":"Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis","volume":"279","author":"Panda","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ajkd.2005.10.007_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.10.007_bib32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.10.007_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","volume":"67","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2005.10.007_bib34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2005.10.007_bib35","first-page":"414","article-title":"The spectrum of renal bone disease","volume":"10","author":"Hamdy","year":"1995","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605015209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605015209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:32:05Z","timestamp":1759455125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638605015209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0272638605015209"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.007","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}